GLP 3-RT-20MG

Description

GLP 3-RT

Retatrutide is an investigational once-weekly injectable “triple-agonist” medication developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials show historic weight loss averaging roughly 24% to 28% of body weight, alongside improvements in blood sugar, fatty liver disease, and osteoarthritis pain. It is not yet FDA-approved.How Retatrutide WorksGLP-1 receptor: Reduces appetite and slows stomach emptying.GIP receptor: Optimizes insulin secretion and fat metabolism.Glucagon receptor: Increases energy expenditure (calorie burning)